<DOC>
	<DOCNO>NCT00167310</DOCNO>
	<brief_summary>The purpose study determine whether administration omega-3 polyunsaturated fatty acid , particularly eicosapentaenoic acid ( EPA ) , useful reduce coronary artery disease ( CAD ) risk illness severity clinically-stable patient schizophrenia ( schizoaffective disorder ) , major depression bipolar disorder ( depressed phase ) treat lipid lower drug ( e.g. , statin ) .</brief_summary>
	<brief_title>Decreasing Risk Coronary Artery Disease Schizophrenia Omega-3 Fatty Acid Supplementation</brief_title>
	<detailed_description>We propose study effect EPA ( 2 g EPA 4 x 500 mg capsule daily ) compare placebo supplementation clinically-stable schizophrenic patient treat statin ( n=30 ) 4 month use randomize , double-blind design . The National Cholesterol Education Program Adult Treatment Panel III guideline use select patient CAD risk participate . Clinical assessment comprehensive assessment risk CAD , include plasma total , high-density lipoprotein ( HDL ) - ( HDL2- HDL3- ) , low-density lipoprotein ( LDL ) - ( LDL-Real- , Lp ( ) - , IDL- ) , VLDL- ( VLDL1,2- VLDL3- ) cholesterol , plasma triglyceride , well plasma homocysteine high sensitivity C-reactive protein , conduct baseline , 1 month , 2 month 4 month supplementation . It anticipate patient receive EPA supplementation significantly great reduction plasma triglyceride LDL4-cholesterol , increase HDL2-cholesterol measure , well improvement psychopathology severity patient receive placebo . If indeed EPA effective decreasing risk CAD , psychiatric benefit EPA supplementation boon patient treatment team . A tremendous advantage clinical use EPA include low cost , significant side effect , ease use .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Patients meet Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIV ) criterion schizophrenia ( schizoaffective disorder ) , major depression , bipolar ( depressed phase ) disorder treat antipsychotic , antidepressant antimanic drug lipidlowering drug ( statin ) 2 month longer screen participate propose project . Based upon CAD risk determinant ( see ) National Cholesterol Education Program ( NCEP ) recommendation goal LDLlowering therapy , investigator enroll schizophrenic patient baseline ( statin treatment ) LDLcholesterol exceed : 70 mg/dL CAD CAD risk equivalent , e.g. , peripheral arterial disease , abdominal aortic aneurysm , symptomatic carotid artery disease , diabetes , well multiple risk factor confer 10year risk CAD &gt; 20 % 130 mg/dL 2 risk factor ; 160 mg/dL less 2 risk factor participate EPA trial . In addition , CADrisk patient reach NCEP goal level within past year follow statin treatment . Risk factor CAD . The NCEP Expert Panel ( NIH Publication No . 013670 , May 2001 ) Detection , Evaluation , Treatment High Blood Cholesterol Adults ( Adult Treatment Panel III ATPIII ) recognize follow CAD risk factor : male , 45 year old , female 55 year old ; family history premature CAD ; current cigarette smoking ; hypertension 140/90 mmHg great ; low HDLcholesterol ( less 40 mg/dL ) . Patients history bleed disorder , current drug alcohol abuse ( within one month ) , neurological disorder ( include head injury loss consciousness great 10 minute ) , antisocial personality disorder , borderline personality disorder , mental retardation indicate medical record Patients pregnant ( determined urine pregnancy test ) Patients already achieve NCEP goal term lipid profile ( indicated laboratory test ) exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Omega-3 fatty acid</keyword>
	<keyword>Statins</keyword>
	<keyword>Antipsychotic drug</keyword>
	<keyword>Antidepressant drug</keyword>
	<keyword>Antimanic drug</keyword>
	<keyword>Placebos</keyword>
	<keyword>Double-blind method</keyword>
	<keyword>Bipolar ( depressed phase )</keyword>
</DOC>